DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination therapy is safe, how well the combination therapy works, and how the body will process DZD9008 when used in combination with bevacizumab.

Trial Details

NCT ID
NCT06276283
Phase
PHASE2
Sponsor
Dizal Pharmaceuticals
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • DZD9008 plus Bevacizumab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Patients must meet all the following criteria for inclusion in the study:
  • Sufficient understanding of nature of the trial and provision of informed consent with hand-written signatures and the date of signature prior to a…
  • Age ≥ 18 years.
  • Histologically or cytologically confirmed and locally advanced or metastatic non-squamous NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →